Cargando…

CD3(bright)CD56(+) T cells associate with pegylated interferon-alpha treatment nonresponse in chronic hepatitis B patients

Chronic hepatitis B (CHB) infection is a serious and prevalent health concern worldwide, and the development of effective drugs and strategies to combat this disease is urgently needed. Currently, pegylated interferon-alpha (peg-IFNα) and nucleoside/nucleotide analogues (NA) are the most commonly pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Chuang, Shen, Xiaokun, Fu, Binqing, Liu, Yanyan, Chen, Yongyan, Ni, Fang, Ye, Ying, Sun, Rui, Li, Jiabin, Tian, Zhigang, Wei, Haiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865958/ https://www.ncbi.nlm.nih.gov/pubmed/27174425 http://dx.doi.org/10.1038/srep25567

Ejemplares similares

NKp30(+) NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B
por: Shen, Xiaokun, et al.
Publicado: (2016)

Immunomodulation Induced During Interferon-α Therapy Impairs the Anti-HBV Immune Response Through CD24(+)CD38(hi) B Cells
por: Fu, Binqing, et al.
Publicado: (2020)

A long noncoding RNA positively regulates CD56 in human natural killer cells
por: Zhang, Ruya, et al.
Publicado: (2016)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Restoration of HBV-specific CD8(+) T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy
por: Wang, Dongyao, et al.
Publicado: (2021)

KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B
por: Li, Wenting, et al.
Publicado: (2017)

Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer Cells
por: Schwane, Vera, et al.
Publicado: (2020)

Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/ Ribavirin Therapy in Chronic Hepatitis C
por: Chu, Po-sung, et al.
Publicado: (2015)

Evaluation of CD56(dim) and CD56(bright) natural killer cells in peripheral blood of women with IVF failures
por: Mardanian, Farahnaz, et al.
Publicado: (2015)

Human Natural Killer Cell Maturation Defect Supports In Vivo CD56(bright) to CD56(dim) Lineage Development
por: Domaica, Carolina Inés, et al.
Publicado: (2012)

NK cells CD56(bright) and CD56(dim) subset cytokine loss and exhaustion is associated with impaired survival in myeloma
por: Seymour, Frances, et al.
Publicado: (2022)

CD56(bright) natural killer cells preferentially kill proliferating CD4(+) T cells
por: Lee, Mercede, et al.
Publicado: (2023)

CD56(dim)CD16(high) and CD56(bright)CD16(−) cell percentages associated with maximum knee extensor strength and incidence of death in elderly
por: Senpuku, Hidenobu, et al.
Publicado: (2016)

Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B
por: Su, Qian, et al.
Publicado: (2018)

The Increased Ratio of Blood CD56(bright) NK to CD56(dim) NK Is a Distinguishing Feature of Primary Sjögren's Syndrome
por: Ming, Bingxia, et al.
Publicado: (2020)

The phenotype of CD3–CD56(bright) and CD3–CD56(dim) natural killer cells in systemic lupus erythematosus patients and its relation to disease activity
por: Soelistyoningsih, Dwi, et al.
Publicado: (2022)

Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B
por: Zhang, Wenhong, et al.
Publicado: (2018)

Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection
por: Vasconcelos, Joana, et al.
Publicado: (2022)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Cytotoxicity of Human Hepatic Intrasinusoidal CD56(bright) Natural Killer Cells against Hepatocellular Carcinoma Cells
por: Hwang, Shin, et al.
Publicado: (2019)

Cytokine-Based Generation of CD49a(+)Eomes(−/+) Natural Killer Cell Subsets
por: Ni, Xiang, et al.
Publicado: (2018)

CD11b(−)CD27(−) NK Cells Are Associated with the Progression of Lung Carcinoma
por: Jin, Jing, et al.
Publicado: (2013)

Ageing is associated with a decline in peripheral blood CD56(bright )NK cells
por: Chidrawar, Shivani M, et al.
Publicado: (2006)

Human Circulating and Tissue-Resident CD56(bright) Natural Killer Cell Populations
por: Melsen, Janine E., et al.
Publicado: (2016)

Circulating CD56(bright) NK cells inversely correlate with survival of melanoma patients
por: de Jonge, Kaat, et al.
Publicado: (2019)

Regulation of Development of CD56(bright)CD11c(+) NK-like Cells with Helper Function by IL-18
por: Li, Wen, et al.
Publicado: (2013)

Reduction of the CD16(−)CD56(bright) NK Cell Subset Precedes NK Cell Dysfunction in Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Loss of CCR7 Expression on CD56(bright) NK Cells Is Associated with a CD56(dim)CD16(+) NK Cell-Like Phenotype and Correlates with HIV Viral Load
por: Hong, Henoch S., et al.
Publicado: (2012)

Human Hepatic CD56(bright) NK Cells Display a Tissue-Resident Transcriptional Profile and Enhanced Ability to Kill Allogenic CD8(+) T Cells
por: Jameson, Gráinne, et al.
Publicado: (2022)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Intratumoral CD56(bright) natural killer cells are associated with improved survival in bladder cancer
por: Mukherjee, Neelam, et al.
Publicado: (2018)

CD56(bright)CD16(-) natural killer cells as an important regulatory mechanism in chronic graft-versus-host disease
por: Lauener, Madeline P., et al.
Publicado: (2022)

Invasive Surgery Impairs the Regulatory Function of Human CD56(bright) Natural Killer Cells in Response to Staphylococcus aureus. Suppression of Interferon-γ Synthesis
por: Reinhardt, Renate, et al.
Publicado: (2015)

CD300c is uniquely expressed on CD56(bright) Natural Killer Cells and differs from CD300a upon ligand recognition
por: Dimitrova, Milena, et al.
Publicado: (2016)

Transcriptome analysis reveals similarities between human blood CD3(−) CD56(bright) cells and mouse CD127(+) innate lymphoid cells
por: Allan, David S. J., et al.
Publicado: (2017)

Oncolytic virus treatment differentially affects the CD56(dim) and CD56(bright) NK cell subsets in vivo and regulates a spectrum of human NK cell activity
por: Wantoch, Michelle, et al.
Publicado: (2022)

Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
por: Thomas, Thea, et al.
Publicado: (2007)

Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56(bright)CD16(−) subset
por: Veneziani, Irene, et al.
Publicado: (2022)

Hobit expression by a subset of human liver-resident CD56(bright) Natural Killer cells
por: Lunemann, Sebastian, et al.
Publicado: (2017)

CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis
por: Laroni, Alice, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u0e5m6ci11164t8v31c2g47frn